Senseonics Holdings Inc

Senseonics operates with a liquidity position that is medium-risk, as indicated by its negative net cash position after subtracting total debt. The company's liquidity FPT (free cash flow to total debt) is weak, with free cash flow of -$68.7 million against long-term debt of $35.6 million. The current ratio of 4.83 suggests strong short-term liquidity, but the negative operating cash flow of -$59.1 million indicates ongoing cash burn. Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of $69.1 million and an operating loss of $68.3 million, with a return on equity of -113.21% and a return on assets of -54.73%. These figures are well below the typical performance of firms in the Medical Equipment, Supplies & Distribution industry, where positive returns and stable margins are expected. Senseonics' revenue is concentrated in a single product line, the Eversense® CGM system, with no disclosed geographic diversification in the provided data. This lack of diversification increases exposure to product-specific risks and regulatory changes in the diabetes management space. The company's growth trajectory is constrained by its current financial position. Revenue for the latest period was $35.3 million, and there is no indication of a significant increase in the near term. The negative operating and net income suggest that the company is not yet achieving sustainable profitability, which is a key requirement for long-term growth in the medical device sector. Risk factors include the company's high debt-to-equity ratio of 0.58 and the absence of positive cash flow generation. The risk assessment indicates a low probability of dilution, but the negative free cash flow and high debt levels could necessitate future capital raises, which may involve equity dilution. The company has not disclosed any recent equity issuance or dilution events in the provided data. Recent events include analyst price targets ranging from $9.00 to $31.00, with a mean of $18.92 and a median of $19.25. The mean recommendation is 2.50, indicating a "hold" consensus among analysts. No strong buy ratings were reported, with five buy and two hold ratings.